SurVaxM Misses Overall Phase IIb Survival Endpoint
MimiVax reported that SurVaxM plus standard therapy did not meet the overall-survival primary endpoint in the randomized Phase IIb SURVIVE trial for newly diagnosed glioblastoma. A prespecified age-65-or-younger subgroup showed improved survival and progression-free…
